Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/222864
Expert consensus on the management of adverse events of Lorlatinib in the treatment of ALK+ advanced non-small cell lung cancer
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
The use of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), such as lorlatinib, for the treatment of patients with ALK gene rearrangement (or ALK-positive) non-small cell lung cancer (NSCLC) has been shown to improve the overall survival and quality of life of these patients. However, lorlatinib is not exempt from potential adverse events. Adequate monitoring and management of these adverse events are critical for increasing patient adherence to lorlatinib, thereby maximizing the benefits of treatment and minimizing the risks associated with treatment discontinuation. Considering that the adverse events of lorlatinib can affect different organs and systems, the participation of a multidisciplinary team, including cardiologists, neurologists, internal medicine specialists, and oncology pharmacists, is needed. This article presents specific and pragmatic strategies for identifying and treating the most relevant adverse events associated with lorlatinib in patients with advanced ALK-positive NSCLC based on the clinical experience of a multidisciplinary panel of experts.
Subject (English)
Citation
Citation
ARRIOLA APERRIBAY, Edurne, et al. Expert consensus on the management of adverse events of Lorlatinib in the treatment of ALK+ advanced non-small cell lung cancer. Clinical Drug Investigation. 2024. Vol. 44, num. 8, pags. 553-576. ISSN 1179-1918. [consulted: 13 of June of 2026]. Available at: https://hdl.handle.net/2445/222864